Use of the wearable cardioverter-defibrillator - the Swiss experience

Boldizsar Kovacs, Sven Reek, Christian Sticherling, Beat Schaer, André Linka, Peter Ammann, Roman Brenner, Nazmi Krasniqi, Andreas S Müller, Omer Dzemali, Richard Kobza, Christian Grebmer (+13 others)
INTRODUCTION Sudden cardiac death caused by malignant arrhythmia can be prevented by the use of defibrillators. Although the wearable cardioverter defibrillator (WCD) can prevent such an event, its role in clinical practice is ill defined. We investigated the use of the WCD in Switzerland with emphasis on prescription rate, therapy adherence and treatment rate. MATERIALS AND METHODS The Swiss WCD Registry is a retrospective observational registry including patients using a WCD. Patients were
more » ... luded from the first WCD use in Switzerland until February 2018. Baseline characteristics and data on WCD usage were examined for the total study population, and separately for each hospital. RESULTS From 1 December 2011 to 18 February 2018, a total of 456 patients (67.1% of all WCDs prescribed in Switzerland and 81.1% of all prescribed in the participating hospitals) were included in the registry. Up to 2017 there was a yearly increase in the number of prescribed WCDs to a maximum of 271 prescriptions per year. The mean age of patients was 57 years (plusmn; 14), 81 (17.8%) were female and mean left ventricular ejection fraction (EF) was 32% (plusmn; 13). The most common indications for WCD use were new-onset ischaemic cardiomyopathy (ICM) with EF le;35% (206 patients, 45.2%), new-onset nonischaemic cardiomyopathy (NICM) with EF le;35% (115 patients, 25.2%), unknown arrhythmic risk (83 patients, 18.2%), bridging to implantable cardioverter-defibrillator implantation or heart transplant (37 patients, 8.1%) and congenital/inherited heart disease (15 patients, 3.3%). Median wear duration was 58 days (interquartile range [IQR] 31ndash;94) with a median average daily wear time of 22.6 hours (IQR 20ndash;23.2). Seventeen appropriate therapies from the WCD were delivered in the whole population (treatment rate: 3.7%) to a total of 12 patients (2.6% of all patients). The most common underlying heart disease in patients with a treatment was ICM (13/17, 76.5%). There were no inappropriate treatments. CONCLUSION The use of WCDs has increased in Switzerland over the years for a variety of indications. There is high therapy adherence to the WCD, and a treatment rate comparable to previously published registry data. nbsp.
doi:10.5167/uzh-198573 fatcat:dueznkiluvagllroxcilbpibae